Table 3.
Characteristics of the included studies of genotypic resistance-guided therapy and empirical quadruple therapy.
| Group | Antibiotics tested determinant | Eradication regime | Eradication rate of TT | Eradication rate of ET | ITT | PP | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Tailored regimens | Empiric regimens | ITT | PP | ITT | PP | RR (95% CI) | p | RR (95% CI) | p | ||
| BQT | 72.7% (232/319) | 84.9% (231/272) | 81.4% (263/323) | 90.8% (258/284) | 0.90 (0.81–1.00) | 0.05 | 0.94 (0.88–1.00) | 0.03 | |||
| Cha 2021 | CLA | CLA-s: AMO 1000 mg BID + CLA 500 mg BID + RAB 20 mg BID, 7 days CLA-r: BIS 300 mg QID + MET 500 mg TID + TET 500 mg QID + RAB 20 mg BID, 7 days |
BIS 300 mg QID + MET 500 mg TID + TET 500 mg QID + RAB 20 mg BID, 7 days | 66.3% (118/178) | 81.4% (118/145) | 78.0% (142/182) | 88.8% (142/160) | 0.85 (0.75–0.97) | 0.92 (0.83–1.01) | ||
| Cho 2021 | CLA | CLA-s: AMO 1000 mg BID + CLA 500 mg BID + PAN 40 mg BID, 7 days CLA-r: BIS 300 mg QID + MET 500 mg TID + TET 500 mg QID + PAN 40 mg BID, 7 days |
BIS 600 mg BID + AMO 1000 mg BID + MET 750 mg BID + PAN 40 mg BID, 14 days | 80.9% (114/141) | 89.0% (113/127) | 85.8% (121/141) | 93.5% (116/124) | 0.94 (0.85–1.05) | 0.95 (0.88–1.03) | ||
| Non-BQT | 83.1% (379/456) | 86.1% (365/424) | 87.7% (379/432) | 90.2% (361/401) | 0.94 (0.89–0.99) | 0.03 | 0.96 (0.91–1.01) | 0.1 | |||
| Choi 2021 | CLA | CLA-s: AMO 1000 mg BID + CLA 500 mg BID + LAN 30 mg BID, 14 days CLA-r: BIS 300 mg QID + MET 500 mg BID + TET 500 mg QID + LAN 30 mg BID, 10 days |
AMO 1000 mg BID + MET 500 mg BID + CLA 500 mg BID + LAN 30 mg BID, 10 days | 82.7% (91/110) | 90.1% (91/101) | 82.2% (88/107) | 91.6% (87/95) | 1.01 (0.89–1.14) | 0.98 (0.90–1.08) | ||
| Kim 2022 | CLA | CLA-s: AMO 1000 mg BID + CLA 500 mg BID + RAB 20 mg BID, 14 days CLA-r: TET 1000 mg QID + MET 500 mg TID + BIS 120 mg QID + RAB 20 mg BID, 14 days |
AMO 1000 mg BID + CLA 500 mg BID + MET 500 mg + RAB 20 mg BID, 14 days | 85.5% (124/145) | 94.6% (122/129) | 82.8% (120/145) | 88.6% (117/132) | 0.90 (0.84–0.98) | 0.94 (0.88–1.00) | ||
| Ong 2019 | CLA | CLA-s: AMO 1000 mg BID + CLA 500 mg BID + LAN 30 mg BID, 14 days CLA-r: AMO 1000 mg BID + MET 500 mg BID + LAN 30 mg BID, 14 days |
AMO 1000 mg BID + CLA 500 mg BID + MET 500 mg BID + LAN 30 mg BID, 14 days | 81.6% (164/201) | 86.5% (154/178) | 86.2% (169/196) | 90.2% (157/174) | 0.95 (0.87–1.03) | 0.93 (0.85–1.03) | ||
| Pooled analysis | 78.8% (611/775) | 85.6% (596/696) | 85.0% (642/755) | 90.4% (619/685) | 0.93 (0.89–0.97) | 0.001 | 0.95 (0.92–0.99) | 0.009 | |||
AMO, amoxicillin; BID, two times a day; BIS, bismuth; CLA, clarithromycin; CLA-r, clarithromycin resistant; CLA-s, clarithromycin sensitive; EPZ, esomeprazole; ET, empirical therapy; LAN, lansoprazole; LEV, levofloxacin; MET, metronidazole; PPI, proton-pump inhibitor; QD, once a day; QID, four times a day.; RAB, rabeprazole; TET, tetracycline; TID, three times a day; TT, tailored therapy.